A Phase II Study of Active Immunotherapy with PANVAC™ or Autologous, Cultured Dendritic Cells Infected with PANVAC™ After Complete Resection of Hepatic Metastases of Colorectal Carcinoma

Lou, Emil; Marshall, John L.; Aklilu, Mebea; Cole, David J.; Chang, David Z.; Morse, Michael A.

doi:10.3816/ccc.2006.n.009

Cited by 20 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An analysis of immune response to the PROSTVAC vaccine on pooled data from several clinical trials conducted similarly reported that 68% of the tested patients exhibited evidence of cross-priming with immune responses mounted against TAAs not found in the vaccine, for example, MUC-1, PSMA, PAP and PSCA, a phenomenon known as antigen spreading [149]. Other applications of the TRICOM vaccine in breast and ovarian cancer [150], solid carcinomas [151,152], colorectal carcinoma [153] or advanced cancers [154] have been tested in phase 1 trials using various antigens and virus vectors, and further studies are planned.…”

Section: Viral Vectorsmentioning

confidence: 99%

Cancer Vaccines

Henriquez¹,

Arkenau²,

Dutoit³

et al. 2019

Cancer Immunotherapy and Biological Cancer Treatments

View full text Add to dashboard Cite

Recent advances in immuno-oncology have allowed for the design of more specific and efficient cancer vaccine approaches. There has been an improvement in molecular biology techniques, as well as a greater understanding of the mechanisms involved in the activation and regulation of T cells and the interplay between the components of the immune system and the escape mechanisms used by cancer cells and the tumour microenvironment. As a result, many interesting developments in therapeutic cancer vaccines are ongoing, with influence on survival still to be proven. The spectrum of tumour antigens that are recognised by T cells is still largely unchartered and, most importantly, dynamically evolving over time, driven by clonal evolution and treatment-driven selection. Vaccine approaches currently in development and tested in clinical studies are based on tumour antigens specifically identified for each tumour type, on tumour cells or dendritic cells, the latter having the potential to be modified to incorporate immunostimulatory genes. However, interplay between the immune system and the tumour and the inhibitory mechanisms developed by tumour cells to subvert immune responses are crucial issues that will need to be targeted in order for efficient therapeutic vaccines to emerge.

show abstract